Affimed N.V. (AFMD), a clinical-stage immuno-oncology company, is gearing up for a clinical trial event next month.
The company is scheduled to report objective response rate (ORR) and safety data from the non-small cell lung cancer (NSCLC) EGFR wild-type (EGFRwt) cohort of its AFM24-102 Phase 1/2a trial on December 17, 2024.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com